ORBIMED ADVISORS LLC Insider Trading $ICPT INTERCEPT PHARMACEUTICALS, INC.
Get free email notifications about insider trading for ORBIMED ADVISORS LLC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of ORBIMED ADVISORS LLC. ORBIMED ADVISORS LLC is 10% Owner in CTI BIOPHARMA CORP ($CTIC) and Director in GLAUKOS Corp ($GKOS) and Director in RESPONSE BIOMEDICAL CORP ($RPBIF) and Director in INTERCEPT PHARMACEUTICALS INC ($ICPT) and in ACCELERON PHARMA INC ($XLRN) and Director in ProNAi Therapeutics Inc ($DNAI) and 10% Owner in AVEDRO INC ($AVDR) and 10% Owner in Relypsa Inc ($RLYP) and 10% Owner in Aerpio Pharmaceuticals, Inc. ($ARPO) and Director in Aerpio Pharmaceuticals, Inc. ($ZETAII) and 10% Owner in CONSTELLATION PHARMACEUTICALS INC ($CNST) and Director in SELECTA BIOSCIENCES INC ($SELB) and Director in SI-BONE, Inc. ($SIBN) and Director in Xtant Medical Holdings, Inc. ($XTNT) and 10% Owner in Roka BioScience, Inc. ($ROKA) and Director in Roka BioScience, Inc. ($ROKA) and 10% Owner in Kala Pharmaceuticals, Inc. ($KALA) and Director in Otonomy, Inc. ($OTIC) and 10% Owner in Arsanis, Inc. ($ASNS) and 10% Owner in Principia Biopharma Inc. ($PRNB) and Director in Acutus Medical, Inc. ($AFIB) and Director in SYNLOGIC, INC. ($MIRN) and 10% Owner in NeuroPace Inc ($NPCE) and 10% Owner in GRAYBUG VISION, INC. ($GRAY) and 10% Owner in Sientra, Inc. ($SIEN) and 10% Owner in TELA Bio, Inc. ($TELA) and Director in Loxo Oncology, Inc. ($LOXO) and 10% Owner in PIERIS PHARMACEUTICALS, INC. ($PIRS) and Director in PIERIS PHARMACEUTICALS, INC. ($PIRS) and Director in Dimension Therapeutics, Inc. ($DMTX) and 10% Owner in Guardant Health, Inc. ($GH) and 10% Owner in ViewRay, Inc. ($VRAY) and Director in ViewRay, Inc. ($VRAY) and Director in Turning Point Therapeutics, Inc. ($TPTX) and in Tricida, Inc. ($TCDA) and Director in Tricida, Inc. ($TCDA) and 10% Owner in Inspire Medical Systems, Inc. ($INSP) and Director in Inspire Medical Systems, Inc. ($INSP) and Director in Synthorx, Inc. ($THOR) and 10% Owner in scPharmaceuticals Inc. ($SCPH) and Director in Adaptimmune Therapeutics PLC ($ADAP) and Director in ALPINE IMMUNE SCIENCES, INC. ($NVLS) and Director in Corvus Pharmaceuticals, Inc. ($CRVS) and 10% Owner in Audentes Therapeutics, Inc. ($BOLD) and Director in Audentes Therapeutics, Inc. ($BOLD) and 10% Owner in SteadyMed Ltd. ($STDY) and 10% Owner in Aeglea BioTherapeutics, Inc. ($AGLE) and 10% Owner in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and Director in Intellia Therapeutics, Inc. ($NTLA) and 10% Owner in Alector, Inc. ($ALEC) and Director in Alector, Inc. ($ALEC) and Director in Decibel Therapeutics, Inc. ($DBTX) and Director in NextCure, Inc. ($NXTC) and Director in LogicBio Therapeutics, Inc. ($LOGC) and Director in Silverback Therapeutics, Inc. ($SBTX) and Director in IMARA Inc. ($IMRA) and Director in Keros Therapeutics, Inc. ($KROS) and Director in Prelude Therapeutics Inc ($PRLD) and Director in PMV Pharmaceuticals, Inc. ($PMVP) and Director in ARMO BioSciences, Inc. ($ARMO) and Director in resTORbio, Inc. ($TORC) and Director in Prevail Therapeutics Inc. ($PRVL) and 10% Owner in SpringWorks Therapeutics, Inc. ($SWTX) and Director in Edgewise Therapeutics, Inc. ($EWTX) and Director in 89bio, Inc. ($ETNB) and Director in Arcutis Biotherapeutics, Inc. ($ARQT) and in Kinnate Biopharma Inc. ($KNTE) and Director in Oric Pharmaceuticals, Inc. ($ORIC) and Director in Repare Therapeutics Inc. ($RPTX) and Director in Fusion Pharmaceuticals Inc. ($FUSN) and Director in Terns Pharmaceuticals, Inc. ($TERN) and Director in Ikena Oncology, Inc. ($IKNA).
ORBIMED ADVISORS LLC in INTERCEPT PHARMACEUTICALS, INC.
Trading Symbol: ICPTIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of ORBIMED ADVISORS LLC: Director
Holdings: 1,120,609 shares
Current Value: $127,267,564
Latest Transaction: Jul 21 2015
$ICPT Market Capitalization: $2.80B
$ICPT Previous Close: $113.57
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of ORBIMED ADVISORS LLC in INTERCEPT PHARMACEUTICALS, INC.
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ETNB, XLRN, AFIB, ADAP, TORC, AGLE, ARPO, ALEC, ALPN, ARQT, ARMO, BOLD, AVDR, CNST, CRVS, CTIC, DBTX, DMTX, EWTX, FUSN, GKOS, GRAY, GH, IKNA, IMRA, INSP, NTLA, ICPT, KALA, KROS, KNTE, LOGC, LOXO, NPCE, NXTC, ORIC, OTIC, PIRS, PMVP, PRLD, PRVL, PRNB, RLYP, RPTX, RPBIF, RYTM, SCPH, SELB, SIBN, SIEN, SRRA, SBTX, ROKA, SWTX, STDY, SYBX, THOR, TELA, TERN, TCDA, TPTX, VRAY, ASNS, XTNT
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jul 21 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Grant | A | 0.00 | 285 | 0 | 1,120,609 | 1.1 M to 1.1 M (+0.03 %) |
Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 294.82 | 90 | 26,534 | 1,120,324 | 1.1 M to 1.1 M (-0.01 %) |
Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 293.85 | 2,500 | 734,625 | 1,120,414 | 1.1 M to 1.1 M (-0.22 %) |
Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 292.13 | 6,000 | 1,752,780 | 1,122,914 | 1.1 M to 1.1 M (-0.53 %) |
Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 291.12 | 3,700 | 1,077,144 | 1,128,914 | 1.1 M to 1.1 M (-0.33 %) |
Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 290.02 | 13,974 | 4,052,739 | 1,132,614 | 1.1 M to 1.1 M (-1.22 %) |
Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 289.07 | 15,131 | 4,373,918 | 1,146,588 | 1.2 M to 1.1 M (-1.30 %) |
Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 288.11 | 26,028 | 7,498,927 | 1,161,719 | 1.2 M to 1.2 M (-2.19 %) |
Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 287.16 | 18,041 | 5,180,654 | 1,187,747 | 1.2 M to 1.2 M (-1.50 %) |
Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 286.24 | 7,611 | 2,178,573 | 1,205,788 | 1.2 M to 1.2 M (-0.63 %) |
Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 285.18 | 23,903 | 6,816,658 | 1,213,399 | 1.2 M to 1.2 M (-1.93 %) |
Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 284.20 | 16,845 | 4,787,349 | 1,237,302 | 1.3 M to 1.2 M (-1.34 %) |
Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 282.87 | 9,357 | 2,646,815 | 1,254,147 | 1.3 M to 1.3 M (-0.74 %) |
Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 282.13 | 8,397 | 2,369,046 | 1,263,504 | 1.3 M to 1.3 M (-0.66 %) |
Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 281.11 | 5,623 | 1,580,682 | 1,271,901 | 1.3 M to 1.3 M (-0.44 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 270.23 | 2,800 | 756,644 | 1,277,524 | 1.3 M to 1.3 M (-0.22 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 275.56 | 3,844 | 1,059,253 | 1,280,324 | 1.3 M to 1.3 M (-0.30 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 275.00 | 12,066 | 3,318,150 | 1,284,168 | 1.3 M to 1.3 M (-0.93 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 273.19 | 2,700 | 737,613 | 1,296,234 | 1.3 M to 1.3 M (-0.21 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 272.13 | 3,050 | 829,997 | 1,298,934 | 1.3 M to 1.3 M (-0.23 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 271.15 | 6,063 | 1,643,982 | 1,301,984 | 1.3 M to 1.3 M (-0.46 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 270.13 | 9,574 | 2,586,225 | 1,308,047 | 1.3 M to 1.3 M (-0.73 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 269.10 | 1,539 | 414,145 | 1,317,621 | 1.3 M to 1.3 M (-0.12 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 268.13 | 6,764 | 1,813,631 | 1,319,160 | 1.3 M to 1.3 M (-0.51 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 288.60 | 1,000 | 288,600 | 1,325,924 | 1.3 M to 1.3 M (-0.08 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 286.04 | 1,400 | 400,456 | 1,326,924 | 1.3 M to 1.3 M (-0.11 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 283.44 | 52 | 14,739 | 1,328,324 | 1.3 M to 1.3 M (0.00 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 283.29 | 1,548 | 438,533 | 1,328,376 | 1.3 M to 1.3 M (-0.12 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 282.00 | 3,500 | 987,000 | 1,329,924 | 1.3 M to 1.3 M (-0.26 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 281.01 | 6,306 | 1,772,049 | 1,333,424 | 1.3 M to 1.3 M (-0.47 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 280.00 | 9,465 | 2,650,200 | 1,339,730 | 1.3 M to 1.3 M (-0.70 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 279.00 | 3,668 | 1,023,372 | 1,349,195 | 1.4 M to 1.3 M (-0.27 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 278.00 | 14,152 | 3,934,256 | 1,352,863 | 1.4 M to 1.4 M (-1.04 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 276.96 | 8,195 | 2,269,687 | 1,367,015 | 1.4 M to 1.4 M (-0.60 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 275.95 | 37,666 | 10,393,933 | 1,375,210 | 1.4 M to 1.4 M (-2.67 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 274.86 | 3,579 | 983,724 | 1,412,876 | 1.4 M to 1.4 M (-0.25 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 273.89 | 11,869 | 3,250,800 | 1,416,455 | 1.4 M to 1.4 M (-0.83 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 272.79 | 8,638 | 2,356,360 | 1,428,324 | 1.4 M to 1.4 M (-0.60 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 271.70 | 7,764 | 2,109,479 | 1,436,962 | 1.4 M to 1.4 M (-0.54 %) |
Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 270.70 | 40,598 | 10,989,879 | 1,444,726 | 1.5 M to 1.4 M (-2.73 %) |
Page: 1